Home > Back to Publisher > Report Information

Indication Expansion Opportunities for Successful Lifecycle Management

Business Insights
March 1, 2007
144 Pages - SKU: RET1471533

Abstract Table of Contents Search inside this report Related Reports

Due to shrinking pipelines and rising financial pressures on pharmaceutical companies, indication expansion is an increasingly attractive strategy to expand patient potential and extend market exclusivity. Indication Expansion is a new report that provides in-depth case studies analyzing successful recent indication expansions and emerging trends. This report will enable you to avoid potential pitfalls whilst gaining a comprehensive review of how to delay generic competition and boost revenue growth. Use the case studies in this report to identify best practice examples of indication expansion strategies and ensure that you can implement these into your current processes to maximize the lifecycle of your products.

Chapter 1 Introduction: Summary; The importance of indication expansion; When an indication expansion is appropriate; Types of indication expansion; Prerequisites for a successful indication expansion; Objectives of indication expansion; Benefits of indication expansion; Building additional revenue streams for a drug; Mitigating the effects of patent expiration
Chapter 2 Extension to related indications: Summary; Introduction; Treatment-prevention extensions
Chapter 3 Extension to new applications: Summary; Introduction; When a new application extension is appropriate
Chapter 4 Pediatric and special population: extensions; Summary; Introduction; Pediatric extensions; Gender-based extensions; When a pediatric or special population extension is appropriate; Objectives of pediatric and special population extensions; Benefits of pediatric and special population extensions; Europe; Limitations of pediatric and special population extensions; Conclusion
Chapter 5 Extension of usage conditions: Summary; Introduction; Monotherapy extensions; When a usage extension is appropriate; Objectives of usage extension; Benefits of usage extension; Conclusion
Chapter 6 Comparison of indication: expansion strategies; Summary; Introduction; Conditions under which each indication expansion strategy is; appropriate; Comparative benefits of each indication expansion strategy; Comparative limitations of each indication expansion strategy; Combining indication expansion strategies; Conclusion
Chapter 7 Appendix: Research methodology; Index
List of Figures: Figure 2.1: Breakdown of new indication launches by therapeutic Area, 2005; Figure 2.2: Comparison of drug development costs by strategy; Figure 3.3: Disease characteristics supporting indication extension for disease variants; Figure 4.4: Botox indications and revenues, 2000 - 2006; Figure 4.5: Pricing opportunities and threats for a new drug indication; Figure 5.6: Timeline of Zyrtec & Claritin US pediatric extensions, 1994 - 2006; Figure 7.7: Comparative appropriateness of indication expansion strategies; Figure 7.8: Comparative benefits of indication expansion strategies; Figure 7.9: Comparative limitations of indication expansion strategies; Figure 7.10: Benefits vs. limitations for indication expansion strategies; Figure 7.11: Singulair indications and revenues, 2002 - 2006
List of Tables: Table 2.1: Selected indication expansions for US commercialized drugs; Table 2.2: Revenues and patent expirations for selected companies’ blockbusters, 2006; Table 3.3: Selected indication extensions for US commercialized drugs; Table 3.4: Impact on global revenues of indication extensions of selected drugs; Table 3.5: Selected indication extension initiatives for US commercialized drugs, 2007; Table 4.6: Selected new application extensions for US commercialized drugs; Table 4.7: Approved and non-approved indications for anti-depressants in the US, 2007; Table 4.8: Impact on global revenues of new additional extensions of selected drugs; Table 4.9: Selected repositioning specialists; Table 4.10: Selected new application extension initiatives for US commercialized drugs; Table 5.11: Selected new application extension initiatives for US commercialized drugs; Table 5.12: Non-approved pediatric usage for US commercialized drugs; Table 6.13: Selected usage extensions for US commercialized drugs; Table 6.14: Selected usage extension initiatives for US commercialized drugs, 2007; Table 7.15: Taxotere indication expansions, 1999 - 2006

Indication Expansion Opportunities for Successful Lifecycle Management

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service